Yhteistyö Chempolis Ltd.'n kanssa on lähtenyt hyvin käyntiin! Ligniini-liiketoiminnan kehittämisestä vastaava päällikkömme Johanna Laukkanen ja tekninen asiantuntijamme Teija Mäyrä ovat tänään seuraamassa ligniinin suodatuskokeita Chempoliksen demolaitoksella Oulussa.
The cooperation with Chempolis Ltd. has started well! Our business development manager Johanna Laukkanen and technical specialist Teija Mäyrä are monitoring lignin filtration tests at the Chempolis demo facility in Oulu today.
🎥 Exciting news! Our latest article on the Dr Morepen "Gluco One" commercial is live. Discover the journey from concept to creation and how we tailored it for the Thai market.
https://lnkd.in/gHntmB-Z
Struggling to get traffic to your webshop? Price comparison platforms can definitely be a game-changer! Get your products in front of ready-to-buy shoppers & boost sales!
Looking forward to share some of my thoughts and experiences on this topic so that you can be prepared for this really important traffic source.
See you soon in Riga 🚀
#ecomriga#ecomriga24#pricecomparison#guenstigerde#cenueksperts
📝We have prepared a comprehensive recap on the conference and partners gathering that took place the last week of September.
We also tell you more about the projects SWITCHtoHEALTHYMEDIET4ALL and PROmedLIFE Tunisia , which took part in the event and are highly linked to DELICIOUS in their activities and goals 💪
Read the full article 👇
If you missed our "fantastic" CTAM Europe session on #AI and #FAST--as one viewer described it--members can view the recording! Very worth watching--we shared some useful info.
Sibaya's rise: From overlooked to overbooked with Devmco Group - Join us to hear about the transformation of Sibaya under Devmco Group, from the initial success of OceanDune to the expansion into new developments.
Tune into the latest segment of Devmco Diaries Unplugged and hear all about the transformation of Sibaya under Devmco Group - https://spoti.fi/3Ka9EMS
Here it is! The last newsletter in the Themis project. In it you can read all about the final partners meeting in Novo mesto and all four multiplier events!
🦐🐟[APA Indonesia] Feel free to meet our team at Techna booth n° 110.
Colleagues and partners coming from Indonesia, India and France will be there to welcome you and discuss subjects such as
✅ Feed cost reduction
✅ Higher fish & shrimp growth
✅ Health support and others
And don’t miss Nicolas Tanrattana oral presentation on the following subject on Friday, July 5: 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗘𝗖𝗢𝗡𝗢𝗠𝗜𝗫 on the growth performance and health condition of Pacific White Shrimp 𝐿𝑖𝑡𝑜𝑝𝑒𝑛𝑎𝑒𝑢𝑠 𝑣𝑎𝑛𝑛𝑎𝑚𝑒𝑖 fed with different levels of palm kernel meal.
Excited for the ALVA10 data team to present their work on how we can make blood based cancer screening (MCED) more palatable for payers, at ISPOR today.
In the US and globally, we have rising rates of cancer in younger populations, being driven largely by the obesity epidemic and environmental factors. People born in 1980 are 4X more likely to get cancer than people born in 1950. Colon cancer will be the #1 cause of death in people age 20-49 by 2030, but current guidelines recommend screening start at age 45. Screening rates in the under 55 population are... not good.
In the US, that means cancer becomes more of a commercial payer issue every year, yet all the focus is on Medicare. Payers are loathe to pay for additional cancer screening- because their budgets are annual.
We can use data, informatics, and genetic information to determine patients who are at elevated risk based on a variety of factors, including genetics, family history, obesity, smoking, and other factors.
If we applied blood based cancer screening (sometimes called MCED- multi-cancer early detection) to the population stratified based on risk, instead of age cutoffs that are based on averages, we would 1) detect more relevant cancer earlier, 2) reduce the total cost of cancer care, and 3) improve survival.
We know a lot of risk factors that are driving the increased rates of cancer in people under 55. We need to apply that information to screening strategy.
ISPOR—The Professional Society for Health Economics and Outcomes Research#diagnostics#precisionmedicine#healtheconomics#cancer
